Publication Name	World Journal of Gastrointestinal Pharmacology and Therapeutics
Manuscript ID	34010
Country	United States

Received	2017-03-21 09:13
Peer-Review Started	2017-03-23 16:51
To Make the First Decision	2017-05-03 14:52
Return for Revision	2017-05-08 20:10
Revised	2017-06-12 14:19
Second Decision	2017-11-06 01:29
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2017-11-10 05:31
Articles in Press	2017-11-10 05:31
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2018-01-25 09:28
Publish the Manuscript Online	2018-02-02 08:28

ISSN	2150-5349 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Study
Article Title	Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting
Manuscript Source	Unsolicited Manuscript
All Author List	Joshua C Berkowitz, Joanna Stein-Fishbein, Sundas Khan, Richard Furie and Keith S Sultan
Funding Agency and Grant Number
Corresponding Author	Keith S Sultan, MD, Assistant Professor, Hofstra Northwell School of Medicine, 300 Community Dr., Manhasset, NY 11030, United States. ksultan@northwell.edu
Key Words	Crohn’s disease; Ulcerative colitis; Infliximab; Azathioprine; Inflammatory bowel disease
Core Tip	In our 13 year experience at a community hospital infusion center, approximately 26% of inflammatory bowel disease patients receiving infliximab infusions received concomitant immunomodulator therapy. This is comparable to rates of combination therapy (CT) at major tertiary referral centers. However, there was a trend of decreased utilization of CT over the study period, even following the publication of SONIC. This suggests a need for further study to define the population with the most favorable risk-benefit ratio from CT, as well as the need for more direct guidelines from major societies.
Publish Date	2018-02-02 08:28
Citation	Berkowitz JC, Stein-Fishbein J, Khan S, Furie R, Sultan KS. Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting. World J Gastrointest Pharmacol Ther 2018; 9(1): 8-13
URL	http://www.wjgnet.com/2150-5349/full/v9/i1/8.htm
DOI	http://dx.doi.org/10.4292/wjgpt.v9.i1.8

Full Article (PDF)	WJGPT-9-8.pdf
Full Article (Word)	WJGPT-9-8.doc
Manuscript File	34010-Review.docx
Answering Reviewers	34010-Answering reviewers.pdf
Audio Core Tip	34010-Audio core tip.mp3
Biostatistics Review Certificate	34010-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	34010-Conflict-of-interest statement.pdf
Copyright License Agreement	34010-Copyright assignment.pdf
Signed Informed Consent Form(s) or Document(s)	34010_34010 Informed Consent Statement.docx
Institutional Review Board Approval Form or Document	34010-Institutional review board statement.pdf
Supplementary Material	34010_34010-Copyright Assignment Pg2 .pdf
Peer-review Report	34010-Peer-review(s).pdf
Scientific Misconduct Check	34010-Scientific misconduct check.pdf
Scientific Editor Work List	34010-Scientific editor work list.pdf